Literature DB >> 25442053

Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin.

A Hugh Mostafid1, Joan Palou Redorta2, Richard Sylvester3, J Alfred Witjes4.   

Abstract

Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25442053     DOI： 10.1016/j.eururo.2014.11.031

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  24 in total

Review 1.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

2.  Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.

Authors:  Andrew T Lenis; Nicholas M Donin; Mark S Litwin; Christopher S Saigal; Julie Lai; Jan M Hanley; Badrinath R Konety; Karim Chamie
Journal:  Clin Genitourin Cancer       Date:  2016-06-25       Impact factor: 2.872

3.  Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Brock E Boehm; John E Cornell; Hanzhang Wang; Neelam Mukherjee; Jacob S Oppenheimer; Robert S Svatek
Journal:  J Urol       Date:  2017-03-10       Impact factor: 7.450

4.  miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition.

Authors:  Jianan Yang; Daozhang Yuan; Jing Li; Shunsheng Zheng; Bin Wang
Journal:  Tumour Biol       Date:  2015-10-23

5.  Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.

Authors:  Andrew T Lenis; Kian Asanad; Maher Blaibel; Nicholas M Donin; Karim Chamie
Journal:  Urol Pract       Date:  2017-03-02

Review 6.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies.

Authors:  Ignacio Melero; Eduardo Castanon; Maite Alvarez; Stephane Champiat; Aurelien Marabelle
Journal:  Nat Rev Clin Oncol       Date:  2021-05-18       Impact factor: 66.675

Review 7.  High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.

Authors:  Rajan Veeratterapillay; Rakesh Heer; Mark I Johnson; Raj Persad; Christian Bach
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

8.  Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.

Authors:  Tracy Downs; Joseph Plasek; John Weissert; Kyle Richards; Kourosh Ravvaz
Journal:  JMIR Cancer       Date:  2021-06-22

Review 9.  Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage.

Authors:  Vignesh T Packiam; Ryan P Werntz; Gary D Steinberg
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 2.862

10.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Authors:  Renate Pichler; Josef Fritz; Claudia Zavadil; Georg Schäfer; Zoran Culig; Andrea Brunner
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.